The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Open accessAbstract
Importance: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. Objective: To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer. Design, Setting, and Participants: Patients (≥18 years) enrolled at community and academic centers throughout the National Clinical Trials Network in the United States and Canada (November 2005-March 2012) with previously untreated advanced or metastatic colorectal cancer whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or bevacizumab (n = 559). The last date of follow-up was December 15, 2015. Interventions: Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient. Main Outcomes and Measures: The primary end point was overall survival. Secondary objectives included progression-free survival and overall response rate, site-reported confirmed or unconfirmed complete or partial response. Results: Among 1137 patients (median age, 59 years; 440 [39%] women), 1074 (94%) of patients met eligibility criteria. As of December 15, 2015, median follow-up for 263 surviving patients was 47.4 months (range, 0-110.7 months), and 82% of patients (938 of 1137) experienced disease progression. The median overall survival was 30.0 months in the cetuximab-chemotherapy group and 29.0 months in the bevacizumab-chemotherapy group with a stratified hazard ratio (HR) of 0.88 (95% CI, 0.77-1.01; P = .08). The median progression-free survival was 10.5 months in the cetuximab-chemotherapy group and 10.6 months in the bevacizumab-chemotherapy group with a stratified HR of 0.95 (95% CI, 0.84-1.08; P = .45). Response rates were not significantly different, 59.6% vs 55.2% for cetuximab and bevacizumab, respectively (difference, 4.4%, 95% CI, 1.0%-9.0%, P = .13). Conclusions and Relevance: Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment. Trial Registration: clinicaltrials.gov identifier: NCT00265850.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, patients with metastatic colorectal cancer and related intestinal malignancies tend to receive similar treatments and live for many months with relatively stable health (median overall survival >2 years) [44], facilitating study completion and potentially derivation of durable benefit from the intervention.”
From Being present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers (2018) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although a higher percentage of men enrolled compared to most prior mindfulness interventions for integrative cancer care [34], the evaluable study sample included a greater proportion of younger (age <50), female, White and Latino or Hispanic patients relative to the underlying population [44, 53].”
From Being present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers (2018) · cites this paper as [44]
Experimental — accuracy not yet measuredIn the citing paper
“This trial demonstrated that patients in the cetuximab plus chemotherapy group had slightly higher overall survival versus patients in the bevacizumab plus chemotherapy group (30.0 months versus 29.0 months).”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [65]
In the citing paper
“Similar to the FIRE-3 trial, median progression-free survival and response rates were similar between groups.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [65]
In the citing paper
“Similarly, the CALGB/SWOG 80405 trial showed that both cetuximab and bevacizumab provided comparable outcomes when combined with chemotherapy in the overall population, but the benefit of anti-EGFR therapy was again limited to RAS wild-type tumors [21].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [21]
In the citing paper
“however, it must be noted here that this pooled analysis also included patients who had received a nonstandard treatment regimen, including FUFIRI, FUFOX, and mIROX as induction chemotherapies and bevacizumab monotherapy or observation alone as maintenance therapies in clinical trials [22,23].”
From The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 2×
“dence indicated that cetuximab activity was unrelated to tumor expression of EGFR.(8) Bevacizumab, a humanized”
BackgroundThe consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“a The 0-to-5 coded scale describing patient daily level of functioning from fully active (0) to completely disabled (4); dead (5).”
BackgroundDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 4×
“Results are reported for (1) the primary 2-group comparison between cetuximab and bevacizumab; (2) the comparison of cetuximab vs bevacizumab in an expanded RAS subset described above; and (3) the chemotherapy subgroups.”
MethodInfluentialSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Cited by
Sorted by citations
Items 601–700 of 900
Li, Y., Lei, Y., Sun, J., Zhang, W., Li, X., Chen, S., Kong, D., Chen, C., Bi, K., Luo, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020400 · Cited by 4
Liu, K., Cui, Y., Li, H., Mi, J., Wang, H., Zhuang, Y., Tang, L., Liu, J., Tian, C., Zhang, Z., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104057 · Cited by 4
Areepium, N., & Sapapsap, B. (2023) · World Journal of Oncology · doi:10.14740/wjon1690 · Cited by 4
“, anti-vascular endothelial growth factor (VEGF) and anti-epidermal growth factor receptor (EGFR) targeted agents, which can prolong patient life expectancy, as an adjunct [2-4].”
BackgroundPräzisionstherapie beim kolorektalen Karzinom
Stintzing, S. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-108467 · Cited by 4
“27,7 Monate; HR = 0,83; p = 0,03) [21].”
BackgroundInfluentialda Silva, W. C., Godman, B., Acúrcio, F. D. A., Cherchiglia, M. L., Martin, A. P., Maruszczyk, K., Izidoro, J. B., Portella, M. A. M., Lana, A. P., Neto, O. H. C., et al. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-020-00626-0 · Cited by 4
Shida, T., Endo, Y., Shiraishi, T., Yoshioka, T., Suzuki, K., Kobayashi, Y., Ono, Y., Ito, T., & Inoue, T. (2017) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.17-00159 · Cited by 4
Suetsugu, T., Matsuhashi, N., Takahashi, T., Tanahashi, T., Matsui, S., Imai, H., Tanaka, Y., Yamaguchi, K., & Yoshida, K. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1742 · Cited by 4
“OS following anti-EGFR monoclonal antibody treatment with CALGB/SWOG80405 (19) was significantly different between right-and left-sided origins.”
Wong, W. W. L., Zargar, M., Berry, S. R., Ko, Y.-J., Martínez, M. C. R., & Chan, K. (2019) · Current Oncology · doi:10.3747/co.26.4843 · Cited by 4
Self-citationTopical application of gemcitabine generates microvesicle particles in human and murine skin
Thyagarajan‐Sahu, A., Awasthi, K., Rapp, C. M., Johnson, R. M., Chen, Y., Miller, K. L., Travers, J. B., & Sahu, R. P. (2022) · BioFactors · doi:10.1002/biof.1924 · Cited by 4
Biomarker Development: Bedside to Bench
Mishkin, G. E., & Kohn, E. C. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0750 · Cited by 4
Characterization of Spatial Heterogeneity in Metastasized Colorectal Cancer by MALDI ImagingPreprint
Moritz, L., Stillger, M. N., Takács, F., Füllgraf, H., Werner, M., Fichtner‐Feigl, S., Jud, A., Schilling, O., & Föll, M. C. (2023) · Preprints.org · doi:10.20944/preprints202302.0363.v1 · Cited by 3
Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift
Robinson, H. R., & Lieu, C. H. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.1088 · Cited by 4
Iguchi, K., Shiozawa, M., UCHIYAMA, M., Asari, M., Numata, K., Rino, Y., & Saito, A. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05805-3 · Cited by 3
“…and vascular endothelial growth factor pathways—have been used extensively to improve the survival of patients with mCRC (Cremo-lini et al. 2015; Venook et al. 2017; Bennouna et al. 2019; Heinrich et al. 2023) Current mCRC treatment guidelines recommend screening for mutations in genes such…”
BackgroundWang, Z., Wu, X., Dai, Q., Liu, Z., Zhao, C., Wei, L. T., Zhao, Y., Li, L., & Wang, X. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103666 · Cited by 4
Immunotherapy for precision medicine in colorectal cancer
Cao, M., Xu, M. Y., Bairmani, Z. A., Bashir, B., Waldman, S. A., & Snook, A. E. (2025) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2025.2560303 · Cited by 3
Wang, Z., Qin, B., Ye, C.-Y., Wang, M., Yuan, L., Yao, H., Jiao, X., Liu, K., Zhou, W., Qin, W., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02383-9 · Cited by 3
Harnessing epigenetics: Genome-wide DNA methylation assay for colorectal cancer therapy
Ishioka, C. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103062 · Cited by 4
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062387 · Cited by 4
“Treatment selection should integrate tumor sidedness, molecular profile, toxicity considerations, comorbidities, and therapeutic goals [71,76,77].”
Choi, M. K., Cha, Y., & Baek, J. Y. (2021) · Oncology · doi:10.1159/000518041 · Cited by 3
Heinemann, V., Singh, M., Hardtstock, F., Hecker, D., Lebioda, A., Schaller-Kranz, T., & Bartsch, R. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.12.002 · Cited by 3
Liver Resection With Extrahepatic Disease: A Population‐Based Analysis of Thoughtful Selection
Mahuron, K. M., Hernandez, M. C., Wong, P., Fan, D., Ituarte, P. H. G., Raoof, M., Singh, G., Fong, Y., & Melstrom, L. G. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27944 · Cited by 4
“Even with the recent advances in chemotherapy regimens, limited survival up to 30 months is reported in highly selected patients with un-resectable disease [18].”
Yang, M., & Yeatman, T. J. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1362316 · Cited by 3
Irinotecan or Oxaliplatin: Which is the First Move for the Mate?
Morelli, C., Formica, V., Riondino, S., Russo, A. D., Ferroni, P., Guadagni, F., & Roselli, M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666201016124950 · Cited by 3
Urban, H., Maurer, G. D., Luger, A., Lorenz, N. I., Sauer, B., Stroh, C., Trojan, J., Mittelbronn, M. G. A., Steinbach, J., Harter, P. N., et al. (2020) · Cancers · doi:10.3390/cancers12103050 · Cited by 3
Moriwaki, T., Gosho, M., Sugaya, A., Yamada, T., Yamamoto, Y., & Hyodo, I. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.805 · Cited by 3
Jacome, A. A. D. A., & Johnson, B. (2021) · EMJ Oncology · doi:10.33590/emjoncol/21-00122 · Cited by 3
Xiong, Q., Zeng, Z., Yang, Y., Wang, Y., Xu, Y., Zhou, Y., Liu, J., Zhang, Z., Qiu, M., & Zhu, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.872630 · Cited by 3
Zhou, X., Aikemu, B., Li, S., Shao, Y., Jia, H., Huang, L., Hong, H., Zhang, S., Tang, Q., Pan, R., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.962575 · Cited by 3
“Studies have shown that patients with RAS mutation or BRAF mutation tend to have a poor prognosis (Jones et al., 2017; Venook et al., 2017).”
BackgroundLei, Y., Li, L., Cheng, S.-Y., Shao, Q., Ding, C., Zuo, R., Chen, W., Liao, Q., & Liu, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1072480 · Cited by 3
Potocki, P. M., Wiśniowski, R., Haus, D., Chowaniec, Z., Kozaczka, M., Kustra, M., Samborska-Plewicka, M., Szweda, M., Starzyczny–Słota, D., Michalik, M., et al. (2023) · Cancers · doi:10.3390/cancers15174361 · Cited by 3
“The characteristics of the population generally followed the patterns of previously published analyses [20,21]; however, the prevalence of RCC turned out to be lower than expected.”
BackgroundElferink, M. A. G., van Erning, F. N., Sijtsma, F. P. C., Iersel, L. V., Wumkes, M. L., Roodhart, J. M. L., & Vink, G. R. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100153 · Cited by 6
Österlund, E., Hammarström, K., Nunes, L., Mathot, L., Mezheyeuski, A., Sjöblom, T., & Glimelius, B. L. G. (2025) · BJC Reports · doi:10.1038/s44276-025-00156-z · Cited by 3
Therapeutische Relevanz molekularer Marker beim kolorektalen Karzinom
Nöpel‐Dünnebacke, S., Conradi, L., Reinacher‐Schick, A., & Ghadimi, M. B. (2020) · Der Onkologe · doi:10.1007/s00761-020-00777-8 · Cited by 3
“So fand man eine signifikante Verbesserung des Überlebens unter einer cetuximabhaltigen Kombinationstherapie gegenüber einer Bevacizumab-Kombination bei Patienten mit linksseitigen Tumoren.”
BackgroundInfluentialCho, M. T., Beechinor, R. J., Gholami, S., & Grothey, A. F. (2021) · Current Colorectal Cancer Reports · doi:10.1007/s11888-021-00466-7 · Cited by 3
Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
Naidoo, M., Piercey, O., & Tie, J. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01137-4 · Cited by 3
Jo, H., Lee, M., Lee, Y.-P., Kim, H.-S., Hong, J. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., et al. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.02.011 · Cited by 5
Shibutani, M., Maeda, K., Nagahara, H., Fukuoka, T., Matsutani, S., Kashiwagi, S., Hirakawa, K., & Ohira, M. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1778 · Cited by 3
Serrano, P. E., Carter, D. N., Li, C., Valencia, M., Ruo, L., Parpia, S., Simunovic, M. R. I., & Levine, O. H. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.01.030 · Cited by 3
Liang, X., & Shen, J. (2019) · Journal of Chemotherapy · doi:10.1080/1120009x.2019.1692282 · Cited by 3
Huang, C., Gu, X., Zeng, X., Chen, B., Yu, W., & Chen, M. (2021) · BMC Cancer · doi:10.1186/s12885-020-07770-9 · Cited by 3
“The superiority of CET over BEV in the clinical setting tends to be positive, which does not deviate from prior studies involving patients with advanced KRAS and BRAF wt CRC [8, 22, 23].”
BackgroundResultInfluentialWeilert, H., Sadeghi, D., Lipp, M., Oldhafer, K. J., Donati, M., & Stang, A. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.06.010 · Cited by 3
Miyamoto, R., Kikuchi, K., Uchida, A., Ozawa, M., Sano, N., Tadano, S., Inagawa, S., Oda, T., & Ohkohchi, N. (2019) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2019.08.010 · Cited by 3
An Evaluation of RAS Testing Among Metastatic Colorectal Cancer Patients in the USA
Sangaré, L. R., Delli-Zotti, K. A., Florea, A., Rehn, M., Benson, A. B., & Lowe, K. A. (2021) · Future Oncology · doi:10.2217/fon-2020-1075 · Cited by 3
Self-citationPartial response of donafenib as the third-line therapy in metastatic colon cancer
Yang, Y., Zhu, H., & Li, Q. (2021) · Medicine · doi:10.1097/md.0000000000027204 · Cited by 3
“In the CALGB 80405 study, a combination of cetuximab and chemotherapy achieved an overall survival of 30.0months, and a mOS of 29.0months was achieved with bevacizumab as first-line treatment for RAS wild-type advanced or metastatic CRC.[9] In the BECOME study, a mOS of 25.7 months was achieved with a combination of b…”
MethodInfluentialCetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer
Lieu, C. H., & Messersmith, W. A. (2017) · JAMA · doi:10.1001/jama.2017.6673 · Cited by 3
Han, H., Li, Y., Qin, W., Wang, L., Yin, H., Su, B., & Yuan, X. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.21.423755 · Cited by 3
Linking Genotype to Phenotype: Bench to Bedside
George, S., & Bertagnolli, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0027 · Cited by 3
Self-citationSekmek, S., Çelebi, S. N. O., Bayram, D., Erol, C., Köş, F. T., Sendur, M. A. N., Altıntaş, Y. E., Tuylu, T., Yıldırım, S., Biter, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-81371-5 · Cited by 3
Associations between early tumor shrinkage/depth of response and survival from the ARCAD database
Bando, H., Takeda, Y., Misumi, T., Nishikawa, T., Wakabayashi, M., Yamazaki, K., Oki, E., Douillard, J., Punt, C. J. A., Koopman, M., et al. (2025) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaf042 · Cited by 2
Self-citationMcKenzie, J., Wong, V., Mendis, S. R., Wong, R., Kosmider, S., To, Y. H., Nott, L. M., Shapiro, J. D., Torres, J., Lee, B., et al. (2025) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2025.04.001 · Cited by 2
Galmarini, C. M., Zamora, R., del Campo, P. G., del Castillo-Izquierdo, J., All, J. A. D., & Domı́nguez, J. M. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03157-4 · Cited by 2
Hsu, H., Chung, H.-Y., You, J., Lee, Y.-S., Chang, J., Hou, H., & Wang, C. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102575 · Cited by 2
“Our study also Recent advancements in mCRC therapy, including biologic agents targeting angiogenesis or proliferation pathways alongside standard chemotherapy, have significantly improved the OS of patients with mCRC, extending it to 24 – 30 months and beyond [36 – 40].”
Nardo, P. D., de Scordilli, M., Giudici, F., Basile, D., Pastò, B., Rota, S., Torresan, S., Bortolot, M., Foltran, L., Guardascione, M., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag011 · Cited by 2
Prognostic Value of Albumin-to-CEA Ratio in Metastatic Colorectal Cancer: A Retrospective Study
Hannarici, Z., Turhan, A., Büyükbayram, M. E., Çağlar, A. A., Bilici, M., Tekin, S. B., Ebinç, S., Yılmaz, A., Ocak, B., Eşdur, P. Ç., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14030579 · Cited by 2
“Instead, it likely mirrors variations in treatment approaches or patient characteristics over time, aligning with earlier findings [58].”
The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer
Kendsersky, N. D., Erlick, M. R., Chen, E., & Kennecke, H. F. (2026) · Cancers · doi:10.3390/cancers18061007 · Cited by 2
“The landmark CALGB/SWOG 80405 trial (NCT00265850) supports this approach, demonstrating an improved overall survival with first-line EGFRi plus chemotherapy in patients with left-sided, RAS-wild-type mCRC, thereby establishing this regimen as a preferred option in this subgroup [5].”
Delahunty, R., Lee, M., Wong, H., Johns, J., McKendrick, J. J., Lee, B., Kosmider, S., Cooray, P. D., Ananda, S. S., Desai, J., et al. (2019) · Internal Medicine Journal · doi:10.1111/imj.14288 · Cited by 2
Lema, M., Franco, B. E. P., Lema, C., Romero-Millán, A. M., Vélez, S. P. M., Fergusson, M. P. R., & Quiceno, D. M. (2021) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.375 · Cited by 2
Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment
Eigėlienė, N., Saarenheimo, J., Wichmann, V., Osterlund, P. J., & Jekunen, A. P. (2021) · Case Reports in Oncology · doi:10.1159/000519044 · Cited by 2
Petrioli, R., Miano, S. T., & Martellucci, I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00007-x · Cited by 2
Stahler, A., Modest, D. P., von Weikersthal, L. F., Kaiser, F., Decker, T. W., Held, S., Graeven, U., Schwaner, I., Denzlinger, C., Schenk, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.019 · Cited by 3
Monoclonal Antibodies for First-Line Treatment of Metastatic Colorectal Cancer
Liao, P., Wu, T., & Peng, T. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001547 · Cited by 2
Biomarkers in Colorectal Cancer: Recent Investigation and Future Prospective
(2023) · NeuroQuantology · doi:10.48047/nq.2023.21.6.nq23120 · Cited by 2
Song, B., Hu, H., Zhang, L., Ye, S., Jin, Y., Shang, C.-L., Zhang, J., Sun, H., Zhang, K., Yi, B., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1238553 · Cited by 2
Lin, Y.-H., Chen, Q.-X., Lu, L., Chen, H., Wu, J., Wang, X., Chen, Y.-Y., Lin, Q., Li, J., & Chen, X. (2023) · PubMed Central · Cited by 2
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer
Arai, H., Yang, Y., Baca, Y., Millstein, J., Denda, T., Ou, F., Innocenti, F., Takeda, H., Kubota, Y., Doi, A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113914 · Cited by 2
Self-citationMarschner, N. W., Seufferlein, T., Potthoff, K., Zahn, M., Uhlig, J., Dörfel, S., Karcher, A., Sauer, A., Maintz, C., Fruehauf, S., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100040 · Cited by 2
Quintanilha, J. C. F., Sibley, A. B., Liu, Y., Niedzwiecki, D., Halabi, S., Rogers, L. W., O’Neil, B. H., Kindler, H. L., Kelly, W. K., Venook, A. P., et al. (2024) · BMC Genomics · doi:10.1186/s12864-024-10354-7 · Cited by 2
“…III study randomizing mCRC patients to receive cetuximab, an epidermal growth factor receptor (EGFR) inhibiting monoclonal antibody, or bevacizumab, a vascular endothelial growth factor (VEGF) inhibiting monoclonal antibody, or the combination of the two in addition to systemic chemotherapy [8].”
BackgroundSelf-citationSanoff, H. K., Deal, A. M., Patel, J. N., Sorah, J. D., Gaddy, J. J., O’Neil, B. H., Turk, A. A., Irvin, W. J., Boles, J. C., Lee, M. S., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae122 · Cited by 2
Self-citationZhang, J., Yang, W., Liu, J., Wang, N., Ren, Z., Yang, T., Xie, G., Wu, G., & Sun, Y. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01443-1 · Cited by 2
Differential functionality of fluoropyrimidine nucleosides for safe cancer therapy
Holzinger, T., Frei, J., Jarzębska, N. T., Beer, H., Kündig, T. M., Pascolo, S., Läuchli, S., & Mellett, M. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001644 · Cited by 2
“In these cases, a combination of bevacizumab and fluoropyrimidine-based chemotherapeutic regimens are used [6,7].”
BackgroundYu, C. (2024) · American Journal of Translational Research · doi:10.62347/rtcx3289 · Cited by 2
Guo, K.-C., Wang, Z., & Su, X. (2024) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-024-4115-8 · Cited by 2
Machida, N., Okumura, T., Boku, N., Kishimoto, J., Nishina, T., Suyama, K., Ohde, Y., Shinozaki, K., Baba, H., Tokunaga, S., et al. (2025) · Cancer · doi:10.1002/cncr.35807 · Cited by 3
Zhao, M., Jiang, Y., Shao, T., & Tang, W. (2025) · Health Economics Review · doi:10.1186/s13561-025-00622-x · Cited by 3
Battaglin, F., O’Neil, B. H., Stintzing, S., Ou, F., Zemla, T., Niedzwiecki, D., Innocenti, F., Höchster, H. S., von Weikersthal, L. F., Decker, T. W., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115694 · Cited by 2
“The CALGB 80405 trial was conducted to compare the efficacy of first-line chemotherapy (FOLFOX or FOLFIRI, based on investigator choice before randomization) plus either cet, bev, or a combination of cet and bev in advanced CRC and mCRC [7].”
Self-citationItalian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer
Rosati, G., Addeo, R., Aprile, G., Avallone, A., Bilancia, D., Brugnatelli, S., Buccafusca, G., Carlomagno, C., Cordio, S. S., Delfanti, S., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03943-x · Cited by 2
ARE WE ALWAYS USING CORRECT APPROACHES IN CANCER TREATMENT?
Moiseenko, F. V., & Moiseyenko, V. M. (2018) · Practical oncology · doi:10.31917/1901016 · Cited by 2
Potemski, P., Bujko, K., Rutkowski, A., & Krzakowski, M. J. (2020) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0030 · Cited by 3
Combined treatment of patients with liver colorectal cancer metastases
Костромицкий, Д. Н., Dobrodeev, А. Y., Afanasyev, S. G., & Tarasova, A. S. (2021) · Annaly khirurgicheskoy gepatologii = Annals of HPB surgery · doi:10.16931/10.16931/1995-5464.2021-2-120-128 · Cited by 2
“Два больших рандомизированных исследования CALGB/SWOG 80405 [50] и FIRE-3 [51] были проведены для сравнения эффективности цетуксимаба и бевацизумаба у больных, получающих химиотерапию по поводу МКРР, однако результаты этих работ оказались неоднозначными.”
Kurreck, A., Heinemann, V., von Weikersthal, L. F., Decker, T. W., Kaiser, F., Uhlig, J., Schenk, M., Freiberg‐Richter, J., Peuser, B., Denzlinger, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.751453 · Cited by 2
Wang, L., Tang, J., Chen, X., Zhao, J., Tang, W., Liao, B., & Nian, W. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055742 · Cited by 2
Zhou, Y., Long, Y., Liu, X., Liu, J., & Qiu, M. (2022) · Future Oncology · doi:10.2217/fon-2021-1422 · Cited by 3
Carlsson, G. U., Koumarianou, A. A., Guren, T. K., Haux, J., Katsaounis, P., Kentepozidis, N. K., Pfeiffer, P., Brændengen, M., Mavroudis, D., Taflin, H. A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100589 · Cited by 2
Chan, A. K. C., & Siriwardena, A. K. (2022) · Cancers · doi:10.3390/cancers14194833 · Cited by 2
“Definitions Used in This Study A colonic primary tumour involving any part of the caecum, ascending colon or the transverse colon up to the splenic flexure was classed as ‘right-sided’ for the purposes of this study [10].”
MethodDo we make progress in elderly patients with metastatic colorectal cancer?
Glimelius, B. L. G., & Pfeiffer, P. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1535189 · Cited by 2
Mukherji, R., Marshall, J. L., & Seeber, A. (2020) · Cancers · doi:10.3390/cancers12082001 · Cited by 2
Rosati, G., & Fé, A. (2020) · Journal of Chemotherapy · doi:10.1080/1120009x.2020.1866823 · Cited by 2
Yazdani, A., Lenz, H., Pillonetto, G., Méndez-Giráldez, R., Yazdani, A., Sanof, H., Hadi, R., Samiei, E., Venook, A. P., Ratain, M. J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3673588/v1 · Cited by 2
Self-citationYazdani, A., Yazdani, A., Méndez-Giráldez, R., Pillonetto, G., Samiei, E., Hadi, R., Lenz, H., Venook, A. P., Samiei, A., Nixon, A. B., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4047331/v1 · Cited by 2
Self-citationEvolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer
Anandappa, G., & Chau, I. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0410-0 · Cited by 1
Wonglhow, J., Sathitruangsak, C., Dechaphunkul, A., & Sunpaweravong, P. (2023) · Journal of International Medical Research · doi:10.1177/03000605231193583 · Cited by 1
“2%, respectively.(29,30) Our study recorded TTP, OS, and ORR of 9 months, 15 months, and 41.”
BackgroundNeoadjuvant chemotherapy in locally advanced rectal cancer
Wei, J., Yuile, A., Harvey, C., Chan, D. L. H., & Diakos, C. I. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015231 · Cited by 1
Yang, W., Chen, D., Niu, Y., Wu, G., Huang, Z., Bi, X., Zhao, H., Che, X., & Sun, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1375906 · Cited by 1
Emmett, M. J., Quintanilha, J. C. F., Graf, R. P., Li, G., Tukachinsky, H., Schrock, A. B., Morley, S., Fisher, V. A., Oxnard, G. R., Lieu, C. H., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100036 · Cited by 1
Shimizu, T., Aoki, T., Ishizuka, M., Sakamoto, K., Beppu, T., Honda, G., Kotake, K., Yamamoto, M., Takahashi, K., Endo, I., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001811 · Cited by 1
Lal, T. S., Kuriachan, S., Kumar, D. M., Pavithran, K., Babu, M., Kartha, N., & Bari, A. (2024) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_9_24 · Cited by 1
Nicholls, D. L., Xu, M. C., Zhan, L. J., Sharma, D., Hueniken, K., Chiasson, K., Wahba, M., Brown, M. C., Grant, B., Shapiro, J. D., et al. (2025) · JCO Clinical Cancer Informatics · doi:10.1200/cci.24.00114 · Cited by 1
Clinical and prognostic characteristics of metastatic colorectal cancer with minor RAS mutations
Kojitani, Y., Sakai, D., Ogata, T., Amano, Y., Mori, R., Kitakaze, M., Sueda, T., Otsuka, T., Nishio, M., Ishihara, M., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.15123 · Cited by 1
Fukuda, K., Osumi, H., Ooki, A., Kamiimabeppu, D., Udagawa, S., Fukuoka, S., Ogura, M., Wakatsuki, T., Chìn, K., Fujishiro, M., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02831-0 · Cited by 1
“Combination chemotherapy with cytotoxic and molecular-targeted drugs has contributed to improved survival of patients with metastatic colorectal cancer (mCRC) [1, 2].”
Pereira, E. G., & da Silva, M. J. S. (2025) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2025v71n3.5223 · Cited by 1
Metadata
- Authors
- Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., Berry, S., Polite, B. N., O'Reilly, E. M., Goldberg, R. M., Hochster, H. S., Schilsky, R. L., Bertagnolli, M. M., El-Khoueiry, A. B., Watson, P., Benson, A. B., Mulkerin, D. L., Mayer, R. J., & Blanke, C.
- Affiliations
- University of California, San Francisco (US)
- Duke University (US)
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- Mayo Clinic (US)
- Dana-Farber/Partners CancerCare, Boston, Massachusetts
- Indiana University, Simon Cancer Center, Indianapolis
- Southeastern Medical Oncology Center (US)
- Sunnybrook Health Science Centre (CA)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Memorial Sloan Kettering Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut
- American Society of Clinical Oncology (US)
- Brigham and Women's Hospital (US)
- Kinston Medical Specialists (US)
- Northwestern University (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-06-20
- Volume
- 317
- Issue
- 23
- Pages
- 2392
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5545896
- OpenAlex
- W2712978371
- Cited by
- 898
- References
- 24
- Citations by year
- 2026: 66 · 2025: 76 · 2024: 87 · 2023: 104 · 2022: 118 · 2021: 118 · 2020: 122 · 2019: 107 · 2018: 82 · 2017: 16
- FWCI
- 39.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (U10CA180882, K05CA169384, U10CA180820, U10CA180791, U10CA180888, U10CA180836, U10CA180790, U10CA180830, U10CA180795, U10CA180850, R01CA149222, U10CA180838, U10CA180867, U10CA180821, U10CA180799)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, KRAS wild-type, cetuximab, bevacizumab, first-line chemotherapy, mFOLFOX6, FOLFIRI, oxaliplatin, irinotecan, monoclonal antibodies, overall survival, progression-free survival, anti-EGFR therapy, anti-VEGF therapy, community oncology
- MeSH terms
- Bevacizumab, Cetuximab, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Canada, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Organoplatinum Compounds, Genes, ras, United States, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Angiogenesis Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
